The newly approved medication offers a needle-free option for adults with high LDL cholesterol, but questions about insurance coverage and affordability remain.
For millions of Americans living with high cholesterol, lowering LDL, often called “bad” cholesterol, has long meant relying on statins or, for some patients, regular injections. That changed Thursday when the U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first once-daily pill that blocks the PCSK9 protein to help reduce LDL cholesterol.
The approval could be especially meaningful in California, where cardiovascular disease continues to affect families across every community, including many Latino households that experience higher rates of risk factors such as diabetes, obesity, and uncontrolled cholesterol. A pill may seem like a small change, but for many patients it could make long-term treatment easier to start and maintain.
Lipfendra belongs to a class of medicines known as PCSK9 inhibitors. Until now, medications in this class were available only as injections.
PCSK9 is a protein that limits the liver’s ability to remove LDL cholesterol from the bloodstream. By blocking that protein, Lipfendra helps the body clear more LDL cholesterol, reducing the buildup that can contribute to heart attacks and strokes.
In clinical trials reviewed by the FDA, participants taking Lipfendra alongside diet and exercise lowered their LDL cholesterol by as much as 60% over six months.
The medication is intended for adults with high cholesterol and is meant to complement, not replace, healthy eating, regular physical activity, and other prescribed treatments.
Why this matters for Latino communities
Heart disease remains one of the leading causes of death among Hispanic and Latino adults in the United States, according to the Centers for Disease Control and Prevention. High cholesterol is one of the major risk factors, yet many people do not know they have elevated LDL levels because the condition usually has no symptoms.
For some patients, injectable medications have been highly effective but difficult to incorporate into daily life. Fear of needles, transportation challenges for medical appointments, or concerns about storing injectable medications have discouraged some people from starting or staying on treatment.
A once-daily pill could remove some of those barriers.
For families balancing work, caregiving responsibilities, and limited time, taking a pill each morning may feel more manageable than scheduling injections or learning how to self-administer them.
Cost could remain the biggest hurdle
Lipfendra’s list price is expected to be about $3,800 per year, or roughly $10.50 a day.
Whether patients actually pay that amount will depend on their insurance coverage.
Because the medication was approved only today, health plans, Medicare Part D, and state Medicaid programs such as Medi-Cal have not yet completed their coverage reviews.
Patients should expect that many insurers will evaluate Lipfendra similarly to existing PCSK9 therapies. That often means doctors must first document that cholesterol remains dangerously high despite treatment with statins or that patients cannot tolerate those medications.
For Californians enrolled in Medi-Cal, coverage decisions are expected after the state’s clinical review process. If approved, out-of-pocket costs are typically much lower than the medication’s retail price, although prior authorization may be required.
Patients with employer-sponsored insurance should also watch for announcements about manufacturer savings programs as the medication becomes available.
Before requesting Lipfendra, consider asking:
- Is my LDL cholesterol high enough for this medication?
- Have I tried the recommended cholesterol-lowering therapies?
- Would Lipfendra work alongside my current medications?
- Will my insurance cover it?
- Are there patient assistance programs available?
These conversations can help patients understand whether the medication fits their personal health needs rather than assuming it is the right option for everyone.
Merck plans to begin making Lipfendra available after the FDA approval, but insurance coverage will likely expand gradually over the coming months.
Doctors, pharmacies, and insurers will begin updating prescribing guidelines and formularies as they review the new treatment.
For patients living with high cholesterol, the approval represents more than another medication. It offers another way to manage a condition that often goes unnoticed until it leads to a heart attack or stroke.
For many California families, especially those who have struggled with injectable treatments or delayed care because of everyday barriers, having a once-daily pill could make staying on treatment a little easier.
It is not a cure, and it will not replace healthy habits, but it gives patients and their healthcare providers another tool to protect long-term heart health.
FAQ
What is Lipfendra?
Lipfendra (enlicitide) is the first FDA-approved daily pill that inhibits PCSK9, helping lower LDL (“bad”) cholesterol.
Who can take Lipfendra?
It is approved for certain adults with high cholesterol. Patients should talk with their healthcare provider to determine whether it is appropriate for their condition.
Does Lipfendra replace statins?
Not necessarily. Some patients may take it in addition to statins or other cholesterol-lowering medications, depending on their treatment plan.
Will Medi-Cal or Medicare cover Lipfendra?
Coverage decisions are still being reviewed because the drug was just approved. Patients should check with their health plan and healthcare provider for the latest information.
Why is this approval important?
Lipfendra is the first oral PCSK9 inhibitor, offering patients a needle-free alternative that may improve treatment adherence while providing another effective option for lowering LDL cholesterol.
Latinos and Heart Attacks: Lower Death Rates, Persistent Risks, and Unequal Care
